Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You could be right, but if ILUS belongs in the trash, may I assume that you've already dumped your shares?
Just curious...
C
Good point(s)...
Thx,
C
Fat chance....if it ever does I think you should play the Lottery...IMMEDIATELY!!!!!!!!
How long of a run is anyone's guess, but this seems like a good start...Global System Dynamics (Ticker GLEE) was trading just north of ten dollars per share at last look and it's a thin trader (just over 13 million shares outstanding...)
I'd aim to have shares in both companies...
C
Fox News anchor Martha MacCallum interviews former US Army intelligence special ops and drone warfare expert Brett Velicovic who called urgently for drone tech from US based companies like Cyberlux to assist with the war effort in the Ukraine ASAP at the 37 second mark of the video below:
It's typical OTC bureaucratic red tape--probably over a missing comma or an extra zero...who knows?
But if Cyberlux fails to deliver the goods I doubt that this temporary road block will prove to be the main reason for it
C
Yes, Fox News anchor Martha MacCallum interviews former US Army intelligence special ops and drone warfare expert Brett Velicovic who called urgently for drone tech from US based companies like Cyberlux to assist with the war effort in the Ukraine ASAP at the 37 second mark of the video below:
I was only posing a question. In an earlier address the CEO stated his plans for Digerati to trade on a senior exchange in the next few months. In order to do that I thought I'd read somewhere that a company has to trade at a floor price of two dollars per share for a minimum of three consecutive months. (I may have gotten that wrong...)
In any event I wanted to know from anyone in this forum who may know better if they think this company can actually reach--or even exceed--a one dollar stock price in the foreseeable future...
FWIW, the CEO said that the price should be around ten cents per share by the end of the year and twenty five cents per share by the end of 2023--both without a reverse split...Now granted, that's not a lot--unless you have millions of shares, but I'll take what I can get...
What about one dollar (or more)?
Does this company have the share structure and capitalization to trade at a buck or higher? I think two dollars per share is the minimum requirement for participation on a senior exchange but I'm not sure...
C
Do you think Digerati will make it to the NASDAQ or other senior trading platform like the NYSE?
And if so, over what approximate time frame?
Just curious,
C
Welcome to what dark side?
What about the interview with Dr. Irwin gives you pause, if anything?
C
I'm a small-fry investor with a minor stake in this company based on the uniqueness of their approach to the treatment of glioblastoma and other potentially lethal cancers...
So what are you saying here--that you expect the stock price to drop to a penny?
If so, why??
End,
C
As with other OTC stocks like DPLS, INTK & ILUS, the only thing that will make share prices bloom at this point are signed contracts with major players and verified financials by respected auditors....Anything less--or other than--that won't cut the mustard with large institutional investors...or with ordinary shareholders for that matter...
Ugh!
C
I hope your forebodings are misplaced but I fear you're right...Fortunately I didn't use the money I set aside for my wife's heart transplant to buy this stock...
C
We all hope you're dead right
C
I certainly respect (and admire) his persistence
C
Why would anyone jump at a chance to buy stock in a company that doesn't deliver the goods in a timely manner? For tax advantages in the form of write-offs?
Disgusted,
C
No kidding...I wish Nick Link and the other administrators there would just shut the fuck up and only make announcements about significant accomplishments AFTER they've been achieved. In response they'll say that if they remain silent for any length of time, the lack of periodic updates depresses interest in the stock. But I think making and missing pre-announced deadlines is more damaging to the psyches of investors than silence since failure to fulfill commitments implies incompetence or dishonesty; often both...
C
Verified financials and signed contracts with industry giants are all that will move this stock upward...Ditto for DPLS, CYBL or any other penny stock...
Until those conditions are met, no one in the wider investment community will give a flying f*ck about ILUS or any of JP Blackwell's rosy forecasts and announcements
JMO,
C
"Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff", "Bottomed & Ready for Liftoff"....
I'm heavily invested in Darkpulse and desperately want this enterprise to be a rousing success but this is beginning to sound delusional
So ILUS owns a small percentage of this gaming company?
The question I would ask is, "Why????"
But is ILUS far enough along in their stateside operations to address a domestic emergency of this size and scope yet?
The 26 minute interview where he mentions the possibility of brain-implanted chips can be found here:
Fun for who???????????????????????????????????????????
I have better things to do with my time and energy than troll downtrodden investors who've put their long term hopes in this company...Dennis O'Leary doesn't impress me either--at least not as a CEO. But at this point you're in or GTFO...
What would I give if the market was as hopeful and enthusiastic about Darkpulse as you, Doog and myself are?
Fat chance...I'd prefer to see a tech giant (like Boeing, Lockheed or Royal Dutch Shell) buy this company out and use their resources to spread this unique infrastructure-monitoring capability around the globe...Will that happen? I hope so, but I doubt DO would relinquish control or ownership of his company unless the potential buyer offered to make him as rich as King Croesus...
You cross your fingers while we cross our toes
C
Good point(s)--particularly about the outstanding shares having more attention drawn to them...
We all hope you're dead right on both counts--particularly the stock price...but I won't complain if the time frame turns out to be a bit shorter...
C
Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...Next week...
Ad infinitum, seemingly...
Disgusted,
C
Realistically, over the next two years or so what approximate stock price do you think Digerati is capable of reaching (or exceeding)?
Just curious...
C
Do you have shares in this company?
If so, why?
If not, what's the point of issuing rants that we've heard from you over and over and over and over and over and over and over and over and over again?
Just curious
If I had a nickel for every 'Ready for Takeoff' pronouncement we've heard in 2022 I'd be farting through silk right now...I hope Dennis can ink at least one major contract prior to year's end--an agreement with an industry whale significant enough to overcome the handicap of our poor share structure and propel us to sustained success both within and beyond our borders...With that in mind, a stock price languishing in the low 2's for this long--particularly after a highly anticipated September 13th conference came and went with scarcely a whimper--is utterly exasperating
C
But who is our new funding partner?
And when did they replace the criminals?
How long ago did Digerati dissociate themselves with this funder?
Just curious...
C
Ok thanks JP!
Agreed...I'm pushing my chips to the center of the table on DTGI and also on a thin trader in the pharmaceutical space--NovAccess Global (ticker XSNX)--which recently got patents approved for an immunological process which addresses an aggressive--and usually fatal--form of brain cancer (glioblastoma)...They've officially uplisted to the QB according to their August 10th Accesswire press release...Both of these stocks have been flapping their wings for quite a while without really getting aloft...With any luck they will sometime next year--hopefully in a big way...
C
CLEVELAND, OH / ACCESSWIRE / September 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the Securities and Exchange Commission ("SEC") has declared the Company's registration statement on Form S-1 effective as of September 16, 2022.
NovAccess Global's Chief Executive Officer Dr. Dwain K. Irvin stated, "The effective registration statement enables, among other things, the distribution of 7.5 million shares of our common stock to Innovest Global, Inc. shareholders, which is a function of the strategic initiatives implemented earlier this year for partially recapitalizing and accelerating the growth of the Company. We are very pleased to have achieved another milestone in our capital formation plan that allows more investors to participate in our future as we advance our unique immunotherapy technology platform targeting a large and significant market for brain tumor therapy."
Dr. Ivin added, "While our common shares were upgraded to the OTC Markets Group's OTCQB® platform from the OTC Pink Market last month, the registration statement and distribution of shares from a single holder to more than 400 recipients is expected to enhance the liquidity of our publicly traded shares by increasing the unaffiliated float as well as the aggregate number of shareholders. These measures are also important for qualification of further uplisting of our common shares to a national exchange, such as Nasdaq or NYSE American."
The registration statement also includes shares held by the Company's lenders and shares issuable upon the conversion of convertible promissory notes or exercise of warrants held by the Company's lenders. Details pertaining to these shares, notes and warrants are included in the S-1 registration statement and were previously filed with the SEC at the time each transaction was consummated.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
Forward-Looking Statement
This press release contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
Investor Relations Contact:
Jordan Darrow
Darrow Associates
631-766-4528
Will Digerati have to do a reverse split in order to facilitate a listing on the NASDAQ?